ABSTRACT
Rosette-forming glioneuronal tumor (RGNT) is a Grade I tumor, which is classified among neuronal and mixed-glial tumors category of the central nervous system by the World Health Organization in their recent classification. It is regarded as an indolent tumor with benign biological behavior. The average age at the time of diagnosis for RGNT is approximately 29, and this tumor preferentially affects young female adults. RGNT is thought to originate from progenitor pluripotential cells of the subependymal plate, capable of differentiating along both glial and neurocytic lines. RGNT often induces nonspecific clinical signs of acute or chronic nature. The clinical and radiological features associated with RGNT are nonspecific. There is no definite consensus for the management of these tumors. Gross total removal, subtotal removal, and biopsy have all been used for treatment in the literature. RGNT usually has a good evolution, progression-free survival, and an overall survival of 100" at 2 years.
